Kara Denby, MD
Interventional Cardiology · Boise, IDNPI 1285053892
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Philips North America LLC at 41.9% of the total. 2025 is the largest year on record at $8,195, more than ten times the $607 reported in 2021. Among interventional cardiology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $120.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$7K
- Abbott$7K
- Boston Scientific$993
- Medtronic$562
- Teleflex LLC$541
- Shockwave Medical, Inc$454
- plus $647 from 9 others
Across 11 payments — averaging $2978.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$33K
What the payments were for
- Consulting fees$1,80010%
- Speaking & faculty fees$5,10029%
- Travel & lodging$4,18724%
- Food & beverage$6,19235%
- Education$2802%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 11 | $7,357 |
| Abbott | 66 | $7,006 |
| Boston Scientific | 22 | $993 |
| Medtronic | 9 | $562 |
| Teleflex LLC | 5 | $541 |
| Shockwave Medical, Inc | 8 | $454 |
| Abiomed | 6 | $223 |
| Edwards Lifesciences | 5 | $177 |
| Terumo Medical Corporation | 3 | $59 |
| Cardiovascular Systems Inc. | 4 | $51 |
| Pfizer | 2 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $35 |
| BD | 1 | $32 |
| Acist Medical Systems, Inc. | 1 | $19 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (R11) US EQ Undivided$5,100
- OPTIS$4,639
- (9520) IGT Devices Undivided$1,668
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$336
- TURNPIKE$281
- Resolute$280
- (5044) MCOT$254
- GENERAL - THERAPIES$187
- (6554) Periph Vasc Undiv$183
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$179
- XIENCE SKYPOINT$154
- GUIDELINER$146
- AVVIGO Guidance System$144
- CARDIOMEMS$142
- SYNERGY$121
- XIENCE SIERRA$117
- PRESSUREWIRE$107
- COROFLOW$102
- ONYX FRONTIER$101
How this compares
$17,559 in reported general payments places this provider in the 95th percentile of 29 interventional cardiology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 93 | $108,616 |
| FarxigaDapagliflozin Propanediol | 13 | $12,705 |
| Metoprolol Succinate | 125 | $1,286 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 79 | $825 |
| Losartan Potassium | 90 | $729 |
| Rosuvastatin Calcium | 81 | $613 |
| Atorvastatin Calcium | 72 | $602 |
| Carvedilol | 76 | $526 |
| Valsartan | 19 | $512 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 19 | $403 |
| Amlodipine Besylate | 98 | $354 |
| Spironolactone | 68 | $335 |
| Warfarin Sodium | 23 | $326 |
| Lisinopril | 56 | $322 |
| Propranolol Hcl ErPropranolol Hcl | 11 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $37 | $108,61693 claims |
| AstraZenecaFarxiga | $14 | $12,70513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 29 interventional cardiology providers in Idaho.
Other interventional cardiology in Boise
- Joseph WalshBoise$115K
- Jeffrey HeslopBoise$17K
- Kendra CoonseBoise$17K
- Patrick ColemanBoise$11K
- Robert DuerrBoise$11K
- Frederick CostelloBoise$5K
- Alex JohnsonBoise$3K
- David CoyleBoise$3K
- Mark ParentBoise$2K
- Carl KapadiaBoise$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.